Earlier charcoal haemoperfusion in fulminant hepatic failure

Charcoal haemoperfusion with a prostacyclin infusion for platelet protection was carried out daily in the treatment of 76 patients with fulminant hepatic failure. in the 31 patients who had been referred early and in whom the serial haemoperfusion was started while signs of grade III encephalopathy...

Full description

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 2; no. 8300; p. 681
Main Authors Gimson, A E, Braude, S, Mellon, P J, Canalese, J, Williams, R
Format Journal Article
LanguageEnglish
Published England 25.09.1982
Subjects
Adult
Brain Edema - prevention & control
Charcoal - therapeutic use
Clinical Trials as Topic
Epoprostenol - pharmacology
Female
Hemoperfusion - adverse effects
Hemoperfusion - instrumentation
Hemoperfusion - methods
Humans
Liver Diseases - mortality
Liver Diseases - pathology
Liver Diseases - therapy
Male
Platelet Adhesiveness - drug effects
Platelet Aggregation - drug effects
Time Factors
Online AccessGet more information

Cover

More Information
Summary:Charcoal haemoperfusion with a prostacyclin infusion for platelet protection was carried out daily in the treatment of 76 patients with fulminant hepatic failure. in the 31 patients who had been referred early and in whom the serial haemoperfusion was started while signs of grade III encephalopathy were still evident remarkable survival rates were obtained-70% for patients with paracetamol poisoning and 65% for the group overall. Cerebral oedema developed significantly less frequently in this group than in those patients in whom haemoperfusion was started later in the course of the disease, when signs of grade IV encephalopathy were already apparent (49% and 78% respectively, p less than 0.05), and this was likely to have been a major factor in their improved survival. Biocompatibility of the system was excellent, and both platelet and white-cell counts at the end of perfusion periods were the same as pre-perfusion values.
ISSN:0140-6736